Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(7 sites)

United States

Emory University School of Medicine: Division of Rheumatology, Atlanta, Georgia

Northwestern University, Chicago, Illinois

Johns Hopkins Hospital: Division of Rheumatology Vasculitis Center, Baltimore, Maryland

Massachusetts General Hospital: Rheumatology, Allergy and Immunology, Center for Immunology and Inflammatory Diseases, Boston, Massachusetts

Northwell Health: Division of Rheumatology and Allergy-Clinical Immunology, Great Neck, New York

Hospital for Special Surgery, New York: Division of Rheumatology, New York, New York

University of Pittsburgh Medical Center: Division of Rheumatology and Clinical Immunology, Pittsburgh, Pennsylvania